Modernland Realty Ltd
MDLN
$35.45
-0.28%
Medline Inc. is the largest provider of medical-surgical products and supply chain solutions in the United States, offering approximately 190,000 Medline-branded products across more than 250 product families—spanning front-line care, surgical solutions, and laboratory and diagnostics—alongside roughly 150,000 third-party products sourced from over 1,250 vendors, with over 90% of revenue generated domestically. The company's competitive identity rests on unmatched scale and vertical integration: more than 30 manufacturing facilities, a fleet of over 2,000 owned delivery trucks, and prime vendor relationships that position it as the primary consolidated logistics partner for many of the largest US health systems, making it a dominant incumbent rather than a disruptor. The current investor narrative is dominated by the company's recent December 2025 IPO and the subsequent reality check of public-market scrutiny, with a major distribution center fire and an FDA warning letter on homecare beds creating near-term operational headwinds that have pressured sentiment. At the same time, bulls point to double-digit revenue growth, a 45,000-employee infrastructure moat, and the argument that Medline's scale should limit long-term damage from these setbacks, framing the selloff as a dislocation rather than a structural impairment.…
MDLN
Modernland Realty Ltd
$35.45
Related headlines
Investment Opinion: Should I buy MDLN Today?
The synthesized recommendation is a Hold with a speculative tilt, reflecting the tension between the company's solid revenue growth and deep valuation discount versus its severe post-IPO downtrend and operational headwinds. The analyst consensus rating of 'buy' (mean 1.56) and average target price of $44.54 imply 25.1% upside, but the market's refusal to bid the stock up suggests investors are waiting for tangible evidence that the operational headwinds have been contained. The core thesis is that Medline's scale and double-digit revenue growth should eventually drive margin recovery, but the timing and magnitude of that recovery remain uncertain.
Supporting evidence for a constructive view includes revenue growth of 11.6% YoY in Q2 2026, well above the low-single-digit growth typical of medical-surgical distributors, and TTM free cash flow of $2.026 billion with an 84.5% FCF conversion rate. The PS ratio of 1.20x is near the bottom of the stock's historical band and likely below the peer group's 1.5x-2.5x range, suggesting a 20-50% discount. The forward PE of 22.58x implies the market expects earnings to roughly triple from trailing levels, consistent with the analyst consensus EPS estimate of $2.29. However, the EV/EBITDA of 22.91x is rich for a distributor, and the net margin of 4.08% and operating margin of 7.78% are below what premium peers deliver.
The biggest risks that could invalidate the thesis are continued margin compression, failure to resolve the FDA warning letter, and further operational disruptions. This Hold would upgrade to Buy if the stock breaks above $40 and gross margins hold above 28%, or if Q3 2026 earnings show net margin recovering above 1.5%. It would downgrade to Sell if revenue growth decelerates below 8% or if the stock breaks below the 52-week low of $31.49 on high volume. Relative to its history and peers, MDLN appears undervalued on a price-to-sales basis but fairly valued to slightly overvalued on EV/EBITDA, making the valuation verdict mixed.
Sign up to view all
MDLN 12-Month Price Forecast
The forward-looking view is cautiously neutral, balancing the company's solid revenue growth and deep valuation discount against its severe post-IPO downtrend and operational headwinds. The forward PE of 22.58x implies the market expects earnings to roughly triple from trailing levels, which is plausible if one-time costs roll off, but the razor-thin net margin of 0.78% in Q2 2026 and thin interest coverage of 2.35x leave little room for error. The analyst consensus buy rating and 25.1% upside to the average target suggest the sell-side views the selloff as overdone, but the market's persistent de-rating signals skepticism. I would upgrade to bullish if Q3 2026 earnings show net margin recovering above 1.5% and the stock breaks above $40, and downgrade to bearish if revenue growth decelerates below 8% or the stock breaks below $31.49.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Modernland Realty Ltd's 12-month outlook, with a consensus price target around $44.50 and implied upside of +25.5% versus the current price.
Average Target
$44.50
0 analysts
Implied Upside
+25.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$34 - $55
Analyst target range
Coverage is robust for a recent IPO, with 26 analysts publishing estimates and a consensus recommendation of "buy" (recommendation mean of 1.56, where 1.0 is a strong buy and 3.0 is a hold). The average price target of $44.54 implies 25.1% upside from the current price of $35.61, a substantial gap that suggests the sell-side views the recent decline as overdone. The consensus leans bullish, with the recommendation mean of 1.56 sitting comfortably in buy territory, and the estimated forward EPS of $2.29 (range $2.27-$2.32) and estimated revenue of $41.94 billion (range $41.64-$42.39 billion) indicate analysts expect continued top-line growth and a sharp earnings recovery. The tight EPS estimate range (a spread of just $0.05) signals high confidence in the near-term earnings trajectory, which contrasts with the wide price target range.
The target range spans $34.00 to $55.00—a 61.8% spread from low to high—which signals meaningful disagreement about the company's fair value. The high target of $55.00 implies roughly 54.5% upside and would require multiple expansion back toward the IPO-era valuation, likely predicated on successful resolution of the FDA issues, full recovery from the distribution center fire, and accelerating revenue growth. The low target of $34.00 implies 4.5% downside and prices in continued margin compression, further operational disruptions, or a broader de-rating of medical-supply distributors. Institutional ratings show a stable-to-constructive pattern: UBS, BTIG, JP Morgan, Tigress, TD Cowen, Stifel, Evercore ISI, Truist, and RBC Capital all maintained Buy/Outperform/Overweight ratings through August and September 2026, with only Wells Fargo maintaining an Equal Weight stance—no downgrades were recorded in the recent period, which suggests analysts are holding their ground despite the price weakness. The wide target spread combined with the absence of recent downgrades implies the sell-side sees the current dislocation as a buying opportunity, but the market's refusal to bid the stock up suggests investors are waiting for tangible evidence that the operational headwinds have been contained.
Bulls vs Bears: MDLN Investment Factors
The bear case currently has stronger evidence due to the stock's severe post-IPO downtrend, razor-thin net margins, and operational disruptions from the distribution center fire and FDA warning letter. However, the bull case rests on solid revenue growth of 11.6% YoY, strong free cash flow of $2.026 billion, and a deep valuation discount with 25.1% analyst upside. The single most important tension is whether the Q2 2026 margin compression—driven by $525 million in one-time other expenses—proves temporary or signals structural margin erosion. If margins recover toward the 2.31% net margin seen in Q4 2025, the stock is deeply undervalued; if they remain depressed, the leveraged balance sheet and thin interest coverage become a serious concern.
Bullish
- Revenue growth accelerating at 11.6% YoY: Q2 2026 revenue of $7.685 billion grew 11.6% year-over-year from $6.886 billion in Q2 2025, and the multi-quarter trend shows consistent expansion from $6.644 billion in Q1 2025 to $7.685 billion in Q2 2026. This growth rate is well above the low-single-digit growth typical of medical-surgical distributors, suggesting Medline is taking share and expanding its prime vendor relationships.
- Analyst consensus buy with 25% upside: 26 analysts cover MDLN with a consensus recommendation of 'buy' (mean 1.56) and an average price target of $44.54, implying 25.1% upside from the current $35.61. No downgrades were recorded through August and September 2026, with UBS, BTIG, JP Morgan, TD Cowen, Stifel, Evercore ISI, Truist, and RBC all maintaining Buy/Outperform ratings.
- Strong free cash flow generation: TTM free cash flow is $2.026 billion, with Q2 2026 FCF of $604 million on operating cash flow of $715 million and capex of just $111 million—an 84.5% FCF conversion rate. This cash generation supports the 1.52% dividend yield and provides flexibility to manage the leveraged balance sheet.
- Deep value on price-to-sales basis: The PS ratio of 1.20x is near the bottom of the stock's historical band and likely below the medical-surgical supply peer group, which typically trades at 1.5x-2.5x sales. This suggests a 20-50% discount to peers on a revenue basis, even after accounting for the EV/Sales of 1.61x.
Bearish
- Severe post-IPO downtrend with -36.71% drawdown: MDLN is down 12.33% year-to-date and 17.55% over three months, sitting just 8.2% above its 52-week low of $31.49 against a 52-week high of $50.876. The max drawdown of -36.71% from peak to trough underscores how severe the post-IPO repricing has been, and the stock has behaved more like a falling knife than a bottoming candidate.
- Razor-thin net margin of 0.78% in Q2 2026: Q2 2026 net income of $60 million on $7.685 billion of revenue equates to a 0.78% net margin, down sharply from 1.75% in Q1 2026 and 2.31% in Q4 2025. The TTM net margin of 4.08% and operating margin of 7.78% are below what premium medical-supply peers deliver, and the Q2 compression was driven by a spike in other expenses to $525 million.
- Leveraged balance sheet with thin interest coverage: The debt-to-equity ratio of 1.17 and total debt-to-capitalization of 52.2% show meaningful leverage, while the cash flow-to-debt ratio of just 0.057 and interest coverage of 2.35x are thin. The company depends on consistent operating performance to service its obligations, leaving little room for error if operational headwinds persist.
- Operational disruptions from fire and FDA warning: A major distribution center fire and an FDA warning letter on homecare beds create significant near-term operational and financial challenges. The FDA flagged serious safety fire risks in Medline homecare beds, and while product removal was avoided, the uncertainty creates ongoing regulatory and reputational risk.
MDLN Technical Analysis
MDLN is in a sustained downtrend that has persisted since shortly after its December 2025 listing, with the stock down 12.33% year-to-date and sitting just 8.2% above its 52-week low of $31.49 against a 52-week high of $50.876. At the current price of $35.61, the stock is trading at approximately 21.0% of its 52-week range—firmly in the lower quartile and closer to the lows than the highs—which signals a market that has been persistently de-rating the shares rather than rewarding momentum. This positioning cuts both ways: it can represent a value opportunity for contrarians, but the absence of any sustained base-building suggests the stock has behaved more like a falling knife than a bottoming candidate over the past several months. The 180-day price history confirms the damage, with a max drawdown of -36.71% from peak to trough, underscoring how severe the post-IPO repricing has been.
Short-term momentum remains weak and, critically, is diverging negatively from an already-weak longer-term trend. The stock is down 1.90% over the past month and 17.55% over the past three months, meaning the 3-month decline is nearly ten times the 1-month decline—momentum is decelerating in its rate of loss but has not yet turned positive. Relative strength tells the more damning story: MDLN has underperformed the S&P 500 by 20.89 percentage points over three months, 36.93 points over six months, and 25.19 points year-to-date, while the 1-month relative strength of -2.49 is a modest improvement that hints at stabilization rather than recovery. The most recent session did show a 1.92% single-day gain on volume of 13.27 million shares, and the short ratio of 6.28 days-to-cover suggests a meaningful short base that could fuel sharp squeezes on any positive catalyst—but one green day does not reverse a six-month downtrend.
Key technical levels are clearly defined: support sits at the 52-week low of $31.49, with the September 2026 lows around $31.64-$32.11 forming a near-term floor, while resistance is anchored at the 52-week high of $50.876 and, more immediately, the $40-$42 zone where the stock repeatedly failed in July and August 2026. A breakdown below $31.49 would signal that the market is pricing in further fundamental deterioration—potentially around the distribution center fire costs or FDA remediation—while a breakout above $40 would be the first credible evidence of a trend reversal. Volatility context matters here: with a max drawdown of -36.71% and a short ratio of 6.28, this is a high-beta, high-uncertainty name where position sizing should account for the possibility of 30%+ swings, and the wide analyst target range (detailed below) reinforces that the market has no consensus on fair value.
Beta
—
—
Max Drawdown
-36.7%
Largest decline past year
52-Week Range
$31-$51
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MDLN Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +0.9% |
| 3m | -13.2% | +3.4% |
| 6m | -22.3% | +14.4% |
| 1y | — | +16.2% |
| ytd | -12.7% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLN Fundamental Analysis
Medline's revenue trajectory remains solidly growth-oriented despite the stock's weakness, with Q2 2026 (quarter ended June 27, 2026) revenue of $7.685 billion representing 11.6% year-over-year growth versus the $6.886 billion reported in Q2 2025. The multi-quarter trend shows consistent expansion: revenue progressed from $6.644 billion in Q1 2025 to $6.886 billion in Q2 2025, $7.115 billion in Q3 2025, $7.787 billion in Q4 2025, $7.352 billion in Q1 2026, and $7.685 billion in Q2 2026—a clear upward trajectory that annualizes to roughly $30 billion. The sequential dip from Q4 2025 to Q1 2026 is typical seasonality, and the re-acceleration in Q2 2026 suggests underlying demand for medical-surgical supplies remains robust, which makes the stock's 17.55% three-month decline look like a sentiment-driven disconnect from operating fundamentals. Revenue segment data was not available, but the company's description indicates the growth is broad-based across its branded and third-party product portfolios.
Profitability is the pressure point. Q2 2026 net income of $60 million on $7.685 billion of revenue equates to a razor-thin 0.78% net margin, down sharply from $129 million (1.75% margin) in Q1 2026 and $180 million (2.31% margin) in Q4 2025. Gross margin in Q2 2026 was 28.82%, an improvement from Q1 2026's 22.65% but still below the 25.11% recorded in Q2 2025, and the trailing twelve-month gross margin of 26.44% sits below the 28.82% quarterly figure—indicating recent quarters are running better than the historical average. The Q2 2026 earnings compression was driven by a spike in other expenses to $525 million (versus $15 million in Q1 2026) and an effective tax rate of 40.85%, both of which look like one-time items related to the distribution center fire and related charges rather than structural margin erosion. Operating margin of 5.14% in Q2 2026 remains thin for a distributor but is consistent with the low-margin, high-volume medical-surgical supply model, and the 7.78% TTM operating margin suggests the business can generate mid-single-digit to high-single-digit operating profitability when not absorbing one-time shocks.
The balance sheet is liquid but leveraged. The current ratio of 4.29 and quick ratio of 2.61 indicate strong short-term liquidity, with $2.329 billion in cash at the end of Q2 2026, but the debt-to-equity ratio of 1.17 and total debt-to-capitalization of 52.2% show meaningful leverage that constrains financial flexibility. Free cash flow remains healthy at $2.026 billion on a TTM basis, with Q2 2026 free cash flow of $604 million on operating cash flow of $715 million and capital expenditure of $111 million—a 84.5% FCF conversion rate that demonstrates the business generates real cash. However, the cash flow-to-debt ratio of just 0.057 and interest coverage of 2.35x are thin, meaning the company depends on consistent operating performance to service its obligations, and the Q4 2025 debt repayment of $4.049 billion alongside $7.048 billion in common stock issued reflects the IPO-related balance sheet restructuring. ROE of 10.79% and ROA of 2.46% are modest but positive, and the 1.52% dividend yield with a 44.7% payout ratio signals management's confidence in cash generation even as the company invests in growth.
Quarterly Revenue
$7.7B
2026-06
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
28.8%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLN Overvalued?
Because Medline is profitable—Q2 2026 net income of $60 million and TTM EPS of $0.034—the PE ratio is the appropriate primary metric, though the trailing PE of 29.37x is distorted by the depressed TTM earnings base. The forward PE of 22.58x is far more informative: it implies the market expects earnings to roughly triple from trailing levels, consistent with the analyst consensus EPS estimate of $2.29 for the forward period versus the current $0.034 trailing figure. The gap between trailing and forward PE—29.37x versus 22.58x—signals that the market is pricing in a sharp earnings recovery as one-time costs (distribution center fire, FDA remediation) roll off and operating leverage improves, but it also means the valuation is highly sensitive to whether that recovery actually materializes.
On a peer-relative basis, Medline's valuation looks mixed. The PS ratio of 1.20x is low in absolute terms and likely below the medical-surgical supply peer group, which typically trades at 1.5x-2.5x sales, suggesting a discount of roughly 20-50% depending on the peer set—though the EV/Sales of 1.61x narrows that gap when debt is included. The EV/EBITDA of 22.91x, however, is rich for a distributor and reflects the depressed EBITDA base; on normalized EBITDA, the multiple would likely compress toward the mid-teens, which would be more in line with peers. The PB ratio of 3.18x is elevated relative to the 1.88x-2.03x range seen in 2025, indicating the market is paying up for book value despite the stock's price decline, and the PEG ratio of -4.96 is meaningless given the negative earnings growth base. The net margin of 4.08% and operating margin of 7.78% are below what premium medical-supply peers deliver, which argues against a premium multiple, but the 11.6% revenue growth rate is above the low-single-digit growth typical of the sector, which argues for one.
Historically, Medline's valuation has compressed dramatically since its IPO. The PE ratio has fallen from 138.8x in Q2 2026 (on the depressed quarterly earnings) to 47.7x in Q4 2025 to 25.0x in Q3 2025, while the PS ratio has declined from 4.33x in Q2 2026 to 4.38x in Q4 2025 to 4.54x in Q3 2025—wait, those PS figures are inconsistent with the current 1.20x, which suggests the historical ratios data may be using a different share count or the stock has repriced dramatically. The PB ratio has risen from 1.88x in Q3 2025 to 3.18x currently, which is the opposite direction of the price, implying book value has grown faster than the share price has fallen. The current PS of 1.20x is near the bottom of the stock's own historical band, which could signal either a deep value opportunity or a market that has permanently re-rated the company lower—the resolution depends on whether the operational headwinds prove temporary.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~70x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.9x
Enterprise Value Multiple
Investment Risk Disclosure
Medline faces significant financial and operational risks stemming from its leveraged balance sheet and thin profitability. The debt-to-equity ratio of 1.17 and total debt-to-capitalization of 52.2% indicate meaningful leverage, while the cash flow-to-debt ratio of just 0.057 and interest coverage of 2.35x are thin, meaning the company depends on consistent operating performance to service obligations. Q2 2026 net income of $60 million on $7.685 billion of revenue equates to a razor-thin 0.78% net margin, down from 2.31% in Q4 2025, driven by a spike in other expenses to $525 million and a 40.85% effective tax rate. The distribution center fire and FDA warning letter on homecare beds create ongoing operational uncertainty, and any further disruptions could exacerbate margin pressure and strain the balance sheet.
Market and competitive risks include valuation compression if the company fails to deliver the earnings recovery implied by the forward PE of 22.58x. The stock has underperformed the S&P 500 by 36.93 percentage points over six months, and the wide analyst target range of $34.00 to $55.00—a 61.8% spread—signals meaningful disagreement about fair value. The EV/EBITDA of 22.91x is rich for a distributor and reflects the depressed EBITDA base; on normalized EBITDA, the multiple would likely compress toward the mid-teens, which would be more in line with peers. Additionally, the FDA warning letter on homecare beds introduces regulatory risk that could escalate if remediation efforts are deemed insufficient, potentially leading to product recalls or further penalties.
The worst-case scenario would involve a combination of continued margin compression, failure to resolve the FDA issues, and further operational disruptions that strain the balance sheet. In this scenario, the stock could retest its 52-week low of $31.49, representing a decline of approximately 11.6% from the current price of $35.61. If the company misses earnings expectations and analysts downgrade the stock, the low target of $34.00 implies 4.5% downside, but a more severe selloff could push the stock below $30, implying a loss of 15-20% from current levels. The max drawdown of -36.71% from peak to trough demonstrates the stock's vulnerability to sharp declines, and with a short ratio of 6.28 days-to-cover, any negative catalyst could trigger a cascade of selling.
FAQ
The most severe risk is financial: the debt-to-equity ratio of 1.17 and interest coverage of 2.35x leave little room for error, and the cash flow-to-debt ratio of 0.057 means the company depends on consistent operating performance to service obligations. Operational risks are also significant, with the distribution center fire and FDA warning letter on homecare beds creating ongoing uncertainty and potential for further disruptions. Competitive risks include the possibility that Medline's scale advantage is eroded by smaller, more agile competitors or by customers shifting to direct sourcing. Macro risks include sensitivity to healthcare spending and interest rates, as the company's leveraged balance sheet makes it vulnerable to rising borrowing costs. Ranked by severity: financial leverage, operational disruptions, regulatory escalation, and competitive pressures.
The 12-month forecast has three scenarios: a bull case with 25% probability targeting $50-$55, a base case with 55% probability targeting $42-$46, and a bear case with 20% probability targeting $30-$34. The base case is most likely, assuming revenue growth holds in the 10-12% range and net margin recovers to 1.5-2.0% by mid-2027, driving the stock toward the analyst average target of $44.54. The bull case requires successful resolution of the FDA issues and full recovery from the distribution center fire, while the bear case assumes continued margin compression and further operational disruptions. The key assumption behind the base case is that the Q2 2026 margin compression was driven by one-time items and will reverse as costs roll off.
MDLN appears undervalued on a price-to-sales basis, with a PS ratio of 1.20x versus the medical-surgical supply peer group's typical 1.5x-2.5x range, suggesting a 20-50% discount. The forward PE of 22.58x implies the market expects earnings to roughly triple from trailing levels, which is plausible if one-time costs roll off. However, the EV/EBITDA of 22.91x is rich for a distributor and reflects the depressed EBITDA base; on normalized EBITDA, the multiple would likely compress toward the mid-teens. The PB ratio of 3.18x is elevated relative to the 1.88x-2.03x range seen in 2025, indicating the market is paying up for book value despite the stock's price decline. Overall, the valuation is mixed: cheap on sales, fair on forward earnings, and expensive on EV/EBITDA, suggesting the market is pricing in a successful earnings recovery but not yet giving credit for it.
MDLN presents a mixed risk/reward profile: the stock trades at $35.61 with 25.1% upside to the analyst average target of $44.54, and the PS ratio of 1.20x is near historical lows. However, the company faces significant near-term headwinds from the distribution center fire and FDA warning letter, and the net margin of 0.78% in Q2 2026 is razor-thin. The stock is down 17.55% over three months and sits just 8.2% above its 52-week low, indicating persistent selling pressure. For risk-tolerant investors with a 12-18 month horizon, the deep valuation discount and strong revenue growth of 11.6% could offer attractive returns if margins recover. For conservative investors, the leveraged balance sheet and thin interest coverage of 2.35x make this a hold at best until there is clearer evidence of operational stabilization.
MDLN is better suited for medium-to-long-term investment (12-18 months minimum) rather than short-term trading, given the company's early-stage post-IPO volatility and the need for operational stabilization. The stock has a max drawdown of -36.71% and a short ratio of 6.28 days-to-cover, indicating high volatility and potential for sharp swings. The dividend yield of 1.52% with a 44.7% payout ratio provides some income, but the primary return driver will be margin recovery and multiple expansion. Earnings visibility is limited due to the recent IPO and ongoing operational issues, making short-term trading risky. A minimum holding period of 12 months is suggested to allow time for the FDA issues to resolve and for margin recovery to materialize.